> It is recommended that some agents which affect haemostasis should be discontinued prior to ENOXAPARIN SODIUM therapy unless strictly indicated. If the combination is indicated, ENOXAPARIN SODIUM should be used with careful clinical and laboratory monitoring whe n appropriate. These agents include medicinal products such as:  
- Systemic salicylates, acetylsalicylic acid at anti -inflammatory doses, and NSAIDs including KETOROLAC,  12 - Other thrombolytics (e.g. ALTEPLASE, RETEPLASE, STREPTOKINASE, TENECTEPLASE, UROKINASE) and anticoagulants (see section 4.2). 
> 
ï‚· Medicinal products increasing POTASSIUM levels:  Medicinal products that increase serum POTASSIUM levels may be administered concurrently with ENOXAPARIN SODIUM under careful clinical and laboratory monitoring (see sections 4.4 and 4.8). 
